Curadel Pharma
Phase 3Leveraging proprietary zwitterionic technology to deliver best-in-class outcomes for targeted alpha therapy (TAT).
Founded
2019
Focus
Radiopharmaceuticals
About
Leveraging proprietary zwitterionic technology to deliver best-in-class outcomes for targeted alpha therapy (TAT).
Funding History
1Total raised: $2M
Seed$2MUndisclosedSep 15, 2021
Company Info
TypePrivate
Founded2019
LocationSan Diego, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile